Thejna John is a happy woman. Last year, the relapse of an acute form of blood cancer despite a bone marrow transplant, had made her doctors give up all hope.

In October, came a breakthrough. India approved the CAR T-Cell therapy, a revolutionary treatment for some forms of cancer. Thejna was one of the first cancer patients to undergo treatment in India. She is now cancer-free.  

The potential of CAR T-cell therapy is significant. And Pharma majors from Dr Reddy’s to Biocon are pouring in money into their own CAR T-Cell projects. But it’s early days. And questions remain: on efficacy, relapse, neurotoxicity and high costs.   

Join the conversation with host Anirban Chowdhury, Vikas Dandekar, ET's pharma expert, along with CAR T-Cell pioneer Dr. Hasmukh Jain, Associate Professor - Tata Memorial Centre, and Shirish Arya, Chief Business Officer - ImmunoACT as they discuss the future of this life-saving treatment on The Morning Brief podcast!

Credits: TED

If you like this episode from Anirban Chowdhury, check out his other interesting episodes on Fatigued & Flying: Why tired pilots are a wake-up call, Vizhinjam Port: Can Adani make India a global shipping hub?, Bhilai to Burj: The Rs. 5,000 Cr Bollywood Studded Mahadev Book Scam and more!

You can follow Anirban Chowdhury on his social media: Twitter and Linkedin

Catch the latest episode of ‘The Morning Brief’ on ET Play, The Economic Times Online, Spotify, Apple Podcasts, Amazon Music and Google Podcasts. 

Thejna John is a happy woman. Last year, the relapse of an acute form of blood cancer despite a bone marrow transplant, had made her doctors give up all hope.
In October, came a breakthrough. India approved the CAR T-Cell therapy, a revolutionary treatment for some forms of cancer. Thejna was one of the first cancer patients to undergo treatment in India. She is now cancer-free.  
The potential of CAR T-cell therapy is significant. And Pharma majors from Dr Reddy’s to Biocon are pouring in money into their own CAR T-Cell projects. But it’s early days. And questions remain: on efficacy, relapse, neurotoxicity and high costs.   
Join the conversation with host <a href="https://m.economictimes.com/etreporter/author-anirban-chowdhury-479232745.cms">Anirban Chowdhury</a>, <a href="https://m.economictimes.com/etreporter/author-vikas-dandekar-479242213.cms">Vikas Dandekar</a>, ET's pharma expert, along with CAR T-Cell pioneer <a href="https://in.linkedin.com/in/hasmukh-jain-851116196">Dr. Hasmukh Jain</a>, Associate Professor - Tata Memorial Centre, and <a href="https://www.linkedin.com/in/shirish-arya-2555891/">Shirish Arya</a>, Chief Business Officer - <a href="https://in.linkedin.com/company/immunoact">ImmunoACT</a> as they discuss the future of this life-saving treatment on The Morning Brief podcast!
Credits: <a href="https://www.youtube.com/watch?v=7qWvVcBZzRg">TED</a>
If you like this episode from Anirban Chowdhury, check out his other interesting episodes on<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000626023069"> Fatigued &amp; Flying: Why tired pilots are a wake-up call</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000632348483"> Vizhinjam Port: Can Adani make India a global shipping hub?</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000631151673"> Bhilai to Burj: The Rs. 5,000 Cr Bollywood Studded Mahadev Book Scam</a> and<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> more</a>!
You can follow Anirban Chowdhury on his social media:<a href="https://twitter.com/AnirbanET"> Twitter</a> and<a href="https://www.linkedin.com/in/anirban-chowdhury-b5067219/"> Linkedin</a> 
Catch the latest episode of ‘The Morning Brief’ on<a href="https://www.etplay.com/etplay"> ET Play</a>,<a href="https://economictimes.indiatimes.com/podcast?from=mdr"> The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> Apple Podcasts</a>,<a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief"> Amazon Music</a> and<a href="https://podcasts.google.com/feed/aHR0cHM6Ly93d3cub21ueWNvbnRlbnQuY29tL2QvcGxheWxpc3QvNjBiMmU5MjYtZTVmOC00YjkwLWE0NjUtYWVmOTAxMTYzMDAxLzk1ZmQ3YzU5LTc5MGQtNDk2ZS1iYmRlLWFlZjkwMTE2N2ZlNC84YWU1NDc2My05OTI1LTQwY2EtOGMzZC1hZWY5MDExNjdmZmIvcG9kY2FzdC5yc3M?sa=X&amp;ved=2ahUKEwi2gOG4la36AhUvjtgFHcdWDU8Q9sEGegQIARAC"> Google Podcasts</a>.

To make sense of the week’s hottest stories in business, economy, politics and markets, journalists from the Economic Times chat with reporters and industry leaders in this thrice-weekly (Tuesday, Thursday, Friday) podcast.